.jpg)
.png)
Volume 17 Issue 3
.color-blue{ color: #23527c; } President of the National Lipid Association for the past year. Thank you to this wonderful organization for allowing me to achieve many of the goals we set for the 2018-2019 year. As you will read below, the theme for my Presidency continues to be leadership... more
.color-blue{ color: #23527c; } As lipid specialists, members of the National Lipid Association (NLA) specialize in the care of patients with complex lipid disorders and most experts utilize a collaborative, multidisciplinary team approach for comprehensive lifestyle and pharmacological... more
.color-blue{ color: #23527c; } Who am I? This is the essential existential question that everyone needs to ask at some point in life. At the National Lipid Association (NLA), this is a question that we will be asking ourselves over the next few years as our field redefines itself. Is it enough... more
Background In the United States, hypertension accounts for more cardiovascular disease (CVD) deaths than any other modifiable CVD risk factor and is second only to cigarette smoking as a preventable cause of death. In 2010, high blood pressure (BP) was the leading cause of death and disability... more
The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial was a randomized trial in 27,564 patients with stable atherosclerotic cardiovascular disease (ASCVD), evaluating evolocumab vs placebo added to statin therapy.(1) The hazard ratio for... more